



Correction to: The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients

Angelo Antonini¹ · Giovanni Abbruzzese² · Alfredo Berardelli^{3,4} · Nicola Modugno⁵ · Italo Stroppa⁶ · Filippo Tamma⁷ · Mariachiara Sensi⁸ · Francesca Mancini⁹ · Giovanni Cossu¹⁰ · Alessandro Stefani¹¹ · Nicola Tambasco¹² · Alessandro Tessitore¹³ · Giovanni Fabbrini^{3,4} · Francesco E. Pontieri¹⁴ · Paolo Solla¹⁵ · Anna Rita Bentivoglio^{16,17} · Cristoforo Comi¹⁸ · Brigida Minafra¹⁹ · Giulio Riboldazzi²⁰ · Donato Melchionda²¹ · Tommaso Martino²¹ · Leonardo Lopiano²²

© Springer-Verlag GmbH Austria, part of Springer Nature 2020

Correction to: Journal of Neural Transmission
<https://doi.org/10.1007/s00702-020-02175-1>

The original version of this article unfortunately contained a mistake. Alfredo Berardelli and Giovanni Fabbrini affiliations were incorrect.

The original article can be found online at <https://doi.org/10.1007/s00702-020-02175-1>.

✉ Angelo Antonini
angelo3000@yahoo.com

- ¹ Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy
- ² Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Child Health, University of Genoa-IRCCS Ospedale Policlinico San Martino, Genova, Italy
- ³ Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
- ⁴ IRCCS Neuromed, Pozzilli, Isernia, Italy
- ⁵ Parkinson Centre-IRCCS Neuromed, Pozzilli, Isernia, Italy
- ⁶ U.O. Dipartimentale di Endoscopia Digestiva Operativa e D'Urgenza, Policlinico Tor Vergata, Rome, Italy
- ⁷ Neurology Unit, Miulli Hospital, Acquaviva delle Fonti, BA, Italy
- ⁸ Neurology Unit, Hospital Sant'Anna, Cona, Ferrara, Italy
- ⁹ UO Neurologia e Stroke Unit e Laboratorio Neuroscienze, Istituto Auxologico San Luca, Milan, Italy
- ¹⁰ SC Neurologia e Stroke Unit, Azienda Ospedaliera Brotzu, Cagliari, Italy
- ¹¹ UOSD Parkinson, Fondazione Policlinico Tor Vergata, Rome, Italy

The correct affiliation of Alfredo Berardelli and Giovanni Fabbrini and author group are given.

In Table 1 there is a little mistake. The mistake is included in the part of the table describing the “Reason to start LCIG”. The corrected Table 1 is placed in the following page.

- ¹² Neurology Department, Perugia General Hospital and University of Perugia, Perugia, Italy
- ¹³ Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania, “Luigi Vanvitelli”, Naples, Italy
- ¹⁴ Department NESMOS, “Sapienza” University, Sant'Andrea Hospital, Rome, Italy
- ¹⁵ Neurology Unit, Policlinico Universitario Monserrato, Cagliari, Italy
- ¹⁶ Institute of Neurology, Università Cattolica del Sacro Cuore, Rome, Italy
- ¹⁷ Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- ¹⁸ Parkinson's Disease and Movement Disorders Centre, Neurology Unit, University of Piemonte Orientale, Novara, Italy
- ¹⁹ Parkinson's Disease and Movement Disorders Unit, IRCCS C. Mondino Foundation, Pavia, Italy
- ²⁰ Parkinson's Disease and Movement Disorders Centre, Neurology Unit, ASST dei Sette Laghi, Varese, Italy
- ²¹ S.C. Neurology, Neuroscience Department, A.O.U. Ospedali Riuniti, University of Foggia, Foggia, Italy
- ²² Department of Neuroscience “Rita Levi-Montalcini”, University of Torino, Torino, Italy

Table 1 Demographics, medical history, PD characteristics, symptoms, motor fluctuations, complications and quality of life (QoL) recorded at BL [mean \pm SD, *N*=(%)]

Gender	
Male	88 (55%)
Female	71 (45%)
Age (years)	69.1 \pm 6.6
Weight (kg)	70.0 \pm 12.5
BMI	25.3 \pm 3.6
Medical history	
Cognitive decline (mild/moderate)	52 (33%)
Psychosis	7 (5%)
Depression	44 (28%)
Compulsive disorder	7 (5%)
Dementia	5 (3%)
Family history	
Parkinson disease	86 (54%)
Parkinsonism	2 (1%)
Tremor	8 (5%)
Other Parkinson syndromes	8 (5%)
Dementia	8 (5%)
PD characteristics	
Time since PD diagnosis (years)	13.6 \pm 5.6
Time since fluctuations (years)	8.4 \pm 4.0
Previous PD treatment	
Levodopa	98%
Dopamine agonist	79%
COMT inhibitors	54%
MAO-B inhibitors	41%
Amantadine	21%
Apomorphine Sc	5%
DBS-STN	3%
Other oral	5%
Severity stage	
Hoehn and Yahr “On”	2.6 \pm 0.7
Hoehn and Yahr “OFF”	3.6 \pm 0.8
PD symptoms	
Tremor [unilateral/bilateral]	90 (57%) [83 (52%)/7 (4%)]
Rigidity [unilateral/bilateral]	97 (61%) [83 (52%)/14 (9%)]
Bradykinesia [unilateral/bilateral]	111 (70%) [80 (52%)/31(20%)]
Postural instability	31 (20%)
Hyposmia	11 (7%)
Anxiety	13 (8%)
Depression	31 (20%)
Apathy	6 (4%)
Others ^a	15 (9%)
Complications	
Pain	63 (42%)
Freezing	85 (5%)
Dystonia	48 (32%)
Fall	72 (47%)
Gait and walking disturbances	96 (63%)
Motor fluctuations	
UDDRS Part III total score in “On” (<i>N</i> = 140)	28.0 \pm 13.3
UDDRS Part III total score in “OFF” (<i>N</i> = 131)	45.8 \pm 13.2

Table 1 (continued)

Complications of therapy	
UPDRS part-IV total score ($N=133$)	8.8 ± 2.9
Quality of life	
PDQ-8 total score ($N=61$)	17.0 ± 8.0
ADL ($N=62$)	4.6 ± 3.4
PDQ-39 total score ($N=39$)	36.7 ± 20.2
Reason to start LCIG	
Motor fluctuations	143 (90%)
Dyskinesia	86 (54%)
Prolonged OFF	105 (66%)
Others ^b	13 (8%)

TANDEM population ($N=159$)

Number of observations in efficacy assessments: UPDRS part-III “On” ($N=140$), UPDRS part-III “OFF” ($N=131$), UPDRS part-IV ($N=133$), PDQ-8 ($N=61$), ADL ($N=62$) and PDQ-38 ($N=39$)

PD Parkinson’s disease, *ADL* activities of daily living, *QoL* quality of life, *UPDRS* Unified Parkinson’s Disease Rating Scale, *PDQ-8* 8-item Parkinson’s Disease Questionnaire, *PDQ-39* 39-item Parkinson’s Disease Questionnaire, *DBS-STN* deep brain stimulation of the subthalamic nucleus, *Sc* subcutaneous, *COMT* catechol-*O*-methyltransferase, *MAO-B* monoamine oxidase

^aAsthenia, headache, pain, gait disturbances, visual disturbances, hypophonia

^bDeep brain stimulation of the subthalamic nucleus, non-motor OFF, blepharospasm, dysphagia, dystonia, freezing, frequent falls